These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9481820)

  • 1. The role of CpG dinucleotides in DNA vaccines.
    Krieg AM; Yi AK; Schorr J; Davis HL
    Trends Microbiol; 1998 Jan; 6(1):23-7. PubMed ID: 9481820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG motifs for optimization of DNA vaccines.
    Davis HL
    Dev Biol (Basel); 2000; 104():165-9. PubMed ID: 11713816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy.
    Kennedy NJ; Spithill TW; Tennent J; Wood PR; Piedrafita D
    Vaccine; 2006 Feb; 24(7):970-9. PubMed ID: 16242220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing vaccines with immune stimulatory CpG DNA.
    Krieg AM; Davis HL
    Curr Opin Mol Ther; 2001 Feb; 3(1):15-24. PubMed ID: 11249727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG motifs in bacterial DNA trigger direct B-cell activation.
    Krieg AM; Yi AK; Matson S; Waldschmidt TJ; Bishop GA; Teasdale R; Koretzky GA; Klinman DM
    Nature; 1995 Apr; 374(6522):546-9. PubMed ID: 7700380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulatory DNA as a vaccine adjuvant.
    Higgins D; Marshall JD; Traquina P; Van Nest G; Livingston BD
    Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant effect of a 14-member macrolide antibiotic on DNA vaccine.
    Sato Y; Shishido H; Kobayashi H; Takeda J; Irisawa A; Miyata M; Nishimaki T; Fujita T; Kasukawa R
    Cell Immunol; 1999 Nov; 197(2):145-50. PubMed ID: 10607432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
    Klinman DM; Yamshchikov G; Ishigatsubo Y
    J Immunol; 1997 Apr; 158(8):3635-9. PubMed ID: 9103425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
    Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
    Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CpG motifs in innate immunity.
    Krieg AM
    Curr Opin Immunol; 2000 Feb; 12(1):35-43. PubMed ID: 10679406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes.
    Stan AC; Casares S; Brumeanu TD; Klinman DM; Bona CA
    Eur J Immunol; 2001 Jan; 31(1):301-10. PubMed ID: 11265647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages.
    Shoda LK; Kegerreis KA; Suarez CE; Mwangi W; Knowles DP; Brown WC
    J Leukoc Biol; 2001 Jul; 70(1):103-12. PubMed ID: 11435492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
    Nesburn AB; Ramos TV; Zhu X; Asgarzadeh H; Nguyen V; BenMohamed L
    Vaccine; 2005 Jan; 23(7):873-83. PubMed ID: 15603887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.